Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:

“Results from negative phase 2 CANOPY-N trial, JTO.

Patients with resectable NSCLC randomized to neoadjuvant canakinumab (anti IL-1β), pembrolizumab, or both. Canakinumab MPR 3%, pembro MPR 17%, combo MPR 17%.

Disappointing but glad results published.”

Title: CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC

Journal: JTO

Authors: Jay M. Lee, Jean-Louis Pujol, Jun Zhang, Oleg Leonov, Masahiro Tsuboi, Edward S. Kim, Calvin Ng, Nicolas Moreno, Amy Cummings, Ilhan Hacibekiroglu, Abidin Sehitogullari, Nirmal Veeramachaneni, Cathy Spillane, Jiawei Duan, Claudia Bossen, Alexander Savchenko, Chiara Lobetti-Bodoni, Tony Mok, Pilar Garrido

Read the full article.

CANOPY-N

More posts featuring Stephen V Liu on OncoDaily.

Stephen V Liu Highlighted CANOPY-N Phase 2 Study in Stage IB–IIIA NSCLC

“Results from negative phase 2 CANOPY-N trial, JTO.

Patients with resectable NSCLC randomized to neoadjuvant canakinumab (anti IL-1β), pembrolizumab, or both. Canakinumab MPR 3%, pembro MPR 17%, combo MPR 17%.

Disappointing but glad results published.”